Glioblastoma multiforme is the most common aggressive adult primary tumour of the central nervous system. Treatment includes surgery, radiotherapy and adjuvant temozolomide (TMZ) …

Temozolomide is an alkylating agent used to treat serious brain cancers; most commonly as second-line treatments for astrocytoma and as the first-line treatment for glioblastoma. [4][6][7] …

Primarily defined histopathologically by necrosis and microvascular proliferation (WHO grade IV classification), glioblastomas are commonly treated through radiotherapy and concomitant …

TMZ has a low molecular weight of 194.154 g/mol, a lipophilic character, and acts as a potent alkylating agent. Currently, TMZ represents the standard adjuvant treatment in newly …

Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of …

The primary endogenous DNA repair mechanisms that counteract the DNA damage caused by TMZ, and are thus commonly implicated in TMZ resistance, include MGMT, BER and MMR. …

2008年6月10日 · Our aim is to present new developments in understanding glioma resistance to alkylating agents and synergy between different treatment modalities (i.e. radiotherapy and …

Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy …

2015年8月26日 · The results of brain tumours treatment with TMZ suggest the new mechanism of modulation epigenetic marker in cancer cells. A high TMZ concentration induced a significant …

2021年3月8日 · Schema of mechanism with involvement of ROS-related factors to take place in mitochondria in temozolomide (TMZ) resistance. Toxicity of TMZ induces excessive …